Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility

被引：49

作者：

Sinn, P. ^{[1
]}

Aulmann, S. ^{[1
]}

Wirtz, R. ^{[2
]}

Schott, S. ^{[3
]}

Marme, F. ^{[3
]}

Varga, Z. ^{[4
]}

Lebeau, A. ^{[5
]}

Kreipe, H. ^{[6
]}

Schneeweiss, A. ^{[7
]}

机构：

[1] Heidelberg Univ, Dept Pathol, D-691234 Heidelberg, Germany

[2] Stratifyer Mol Pathol GmbH, Cologne, Germany

[3] Heidelberg Univ, Dept Obstet & Gynaecol, D-691234 Heidelberg, Germany

[4] Univ Zurich Hosp, Inst Surg Pathol, CH-8091 Zurich, Switzerland

[5] Univ Med Canter Hamburg Eppendorf, Dept Pathol, Hamburg, Germany

[6] Hannover Med Sch, Inst Pathol, D-30623 Hannover, Germany

[7] Natl Ctr Tumor Dis, Heidelberg, Germany

来源：

GEBURTSHILFE UND FRAUENHEILKUNDE | 2013年 / 73卷 / 09期

关键词：

breast cancer; multigene assays; prognosis; GENOMIC GRADE INDEX; INTERNATIONAL EXPERT CONSENSUS; EXPRESSION-BASED PREDICTORS; GENE-EXPRESSION; ESTROGEN-RECEPTOR; INTRINSIC SUBTYPES; RECURRENCE SCORE; MOLECULAR PORTRAITS; ADJUVANT TAMOXIFEN; HISTOLOGIC GRADE;

D O I：

10.1055/s-0033-1350831

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-) adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50 (R), MammaTyper (R), MammaPrint (R), Oncotype DX (R), Endopredict (R), Genomic Grade Index (R)) and IHC risk scores (Mammostrat (R) and IHC4), and discuss the current evidence of their clinical use.

引用

页码：932 / 940

页数：9

共 89 条

[1] Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].

Albain, K. ;

Anderson, S. ;

Arriagada, R. ;

Barlow, W. ;

Bergh, J. ;

Bliss, J. ;

Buyse, M. ;

Cameron, D. ;

Carrasco, E. ;

Clarke, M. ;

Correa, C. ;

Coates, A. ;

Collins, R. ;

Costantino, J. ;

Cutter, D. ;

Cuzick, J. ;

Darby, S. ;

Davidson, N. ;

Davies, C. ;

Davies, K. ;

Delmestri, A. ;

Di Leo, A. ;

Dowsett, M. ;

Elphinstone, P. ;

Evans, V. ;

Ewertz, M. ;

Gelber, R. ;

Gettins, L. ;

Geyer, C. ;

Goldhirsch, A. ;

Godwin, J. ;

Gray, R. ;

Gregory, C. ;

Hayes, D. ;

Hill, C. ;

Ingle, J. ;

Jakesz, R. ;

James, S. ;

Kaufmann, M. ;

Kerr, A. ;

MacKinnon, E. ;

McGale, P. ;

McHugh, T. ;

Norton, L. ;

Ohashi, Y. ;

Paik, S. ;

Pan, H. C. ;

Perez, E. ;

Peto, R. ;

Piccart, M. .

LANCET, 2012, 379 (9814) :432-444

[2] Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial [J].

Albain, Kathy S. ;

Barlow, William E. ;

Shak, Steven ;

Hortobagyi, Gabriel N. ;

Livingston, Robert B. ;

Yeh, I-Tien ;

Ravdin, Peter ;

Bugarini, Roberto ;

Boehner, Frederick L. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Winer, Eric P. ;

Hudis, Clifford ;

Ingle, James N. ;

Perez, Edith A. ;

Pritchard, Kathleen I. ;

Shepherd, Lois ;

Gralow, Julie R. ;

Yoshizawa, Carl ;

Allred, D. Craig ;

Osborne, C. Kent ;

Hayes, Daniel F. .

LANCET ONCOLOGY, 2010, 11 (01) :55-65

[3] Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement [J].

Azim, H. A., Jr. ;

Michiels, S. ;

Zagouri, F. ;

Delaloge, S. ;

Filipits, M. ;

Namer, M. ;

Neven, P. ;

Symmans, W. F. ;

Thompson, A. ;

Andre, F. ;

Loi, S. ;

Swanton, C. .

ANNALS OF ONCOLOGY, 2013, 24 (03) :647-654

[4] Mammostrat As an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in the Tamoxifen Versus Exemestane Adjuvant Multicenter Trial Pathology Study [J].

Bartlett, John M. S. ;

Bloom, Kenneth J. ;

Piper, Tammy ;

Lawton, Thomas J. ;

van de Velde, Cornelis J. H. ;

Ross, Douglas T. ;

Ring, Brian Z. ;

Seitz, Robert S. ;

Beck, Rodney A. ;

Hasenburg, Annette ;

Kieback, Dirk ;

Putter, Hein ;

Markopoulos, Christos ;

Dirix, Luc ;

Seynaeve, Caroline ;

Rea, Daniel .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) :4477-4484

[5] Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer [J].

Barton, S. ;

Zabaglo, L. ;

A'Hern, R. ;

Turner, N. ;

Ferguson, T. ;

O'Neill, S. ;

Hills, M. ;

Smith, I. ;

Dowsett, M. .

BRITISH JOURNAL OF CANCER, 2012, 106 (11) :1760-1765

[6] PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers [J].

Bastien, Roy R. L. ;

Rodriguez-Lescure, Alvaro ;

Ebbert, Mark T. W. ;

Prat, Aleix ;

Munarriz, Blanca ;

Rowe, Leslie ;

Miller, Patricia ;

Ruiz-Borrego, Manuel ;

Anderson, Daniel ;

Lyons, Bradley ;

Alvarez, Isabel ;

Dowell, Tracy ;

Wall, David ;

Angel Segui, Miguel ;

Barley, Lee ;

Boucher, Kenneth M. ;

Alba, Emilio ;

Pappas, Lisa ;

Davis, Carole A. ;

Aranda, Ignacio ;

Fauron, Christiane ;

Stijleman, Inge J. ;

Palacios, Jose ;

Anton, Antonio ;

Carrasco, Eva ;

Caballero, Rosalia ;

Ellis, Matthew J. ;

Nielsen, Torsten O. ;

Perou, Charles M. ;

Astill, Mark ;

Bernard, Philip S. ;

Martin, Miguel .

BMC MEDICAL GENOMICS, 2012, 5

[7] Oncotype DX Test on Unequivocally HER2-Positive Cases: Potential for Harm [J].

Bhargava, Rohit ;

Dabbs, David J. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) :570-571

[8] Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients [J].

Bichlien Nguyen ;

Cusumano, Pino G. ;

Deck, Kenneth ;

Kerlin, Deborah ;

Garcia, Agustin A. ;

Barone, Julie L. ;

Rivera, Edgardo ;

Yao, Katharine ;

de Snoo, Femke A. ;

van den Akker, Jeroen ;

Stork-Sloots, Lisette ;

Generali, Daniele .

ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (10) :3257-3263

[9] Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies [J].

Blows, Fiona M. ;

Driver, Kristy E. ;

Schmidt, Marjanka K. ;

Broeks, Annegien ;

van Leeuwen, Flora E. ;

Wesseling, Jelle ;

Cheang, Maggie C. ;

Gelmon, Karen ;

Nielsen, Torsten O. ;

Blomqvist, Carl ;

Heikkila, Paivi ;

Heikkinen, Tuomas ;

Nevanlinna, Heli ;

Akslen, Lars A. ;

Begin, Louis R. ;

Foulkes, William D. ;

Couch, Fergus J. ;

Wang, Xianshu ;

Cafourek, Vicky ;

Olson, Janet E. ;

Baglietto, Laura ;

Giles, Graham G. ;

Severi, Gianluca ;

McLean, Catriona A. ;

Southey, Melissa C. ;

Rakha, Emad ;

Green, Andrew R. ;

Ellis, Ian O. ;

Sherman, Mark E. ;

Lissowska, Jolanta ;

Anderson, William F. ;

Cox, Angela ;

Cross, Simon S. ;

Reed, Malcolm W. R. ;

Provenzano, Elena ;

Dawson, Sarah-Jane ;

Dunning, Alison M. ;

Humphreys, Manjeet ;

Easton, Douglas F. ;

Garcia-Closas, Montserrat ;

Caldas, Carlos ;

Pharoah, Paul D. ;

Huntsman, David .

PLOS MEDICINE, 2010, 7 (05)

[10] Intrinsic breast cancer subtypes defined by estrogen receptor signalling-prognostic relevance of progesterone receptor loss [J].

Braun, Lisa ;

Mietzsch, Friederike ;

Seibold, Petra ;

Schneeweiss, Andreas ;

Schirmacher, Peter ;

Chang-Claude, Jenny ;

Sinn, Hans Peter ;

Aulmann, Sebastian .

MODERN PATHOLOGY, 2013, 26 (09) :1161-1171

← 1 2 3 4 5 6 7 8 9 →